What is the appropriate episodic therapy for recurrent genital HSV‑2 infection in adults, including first‑line oral antiviral regimens and dosing adjustments for renal impairment?

Episodic Treatment of HSV-2

For recurrent genital HSV-2 infection, initiate oral antiviral therapy at the first sign of prodrome or lesions with one of the following first-line regimens: valacyclovir 500 mg twice daily for 3-5 days, acyclovir 800 mg twice daily for 5 days, or famciclovir 125 mg twice daily for 5 days.

First-Line Treatment Regimens

The CDC guidelines provide multiple equivalent options for episodic therapy 1:

Preferred regimens (all for 5 days unless noted):

• Valacyclovir 500 mg orally twice daily (can be shortened to 3 days with equivalent efficacy 2)
• Acyclovir 800 mg orally twice daily
• Acyclovir 400 mg orally three times daily
• Acyclovir 200 mg orally five times daily
• Famciclovir 125 mg orally twice daily

Valacyclovir and famciclovir offer superior convenience with twice-daily dosing compared to acyclovir's multiple daily doses, which is particularly important for patient adherence 1. Research demonstrates that a 3-day course of valacyclovir 500 mg twice daily is equivalent to the standard 5-day course for all efficacy endpoints including lesion healing time (4.4 vs 4.7 days), pain duration, and episode length 2.

Critical Timing for Maximum Benefit

Treatment must be initiated during the prodrome or within 1 day of lesion onset to achieve meaningful clinical benefit 1. This narrow therapeutic window means patients should be provided with a prescription or medication supply in advance to enable immediate self-initiation at the first sign of symptoms 1.

The evidence shows that when treatment starts during prodrome or within 24 hours of lesion onset, episodic therapy significantly:

• Shortens lesion duration (median 4 days vs 6 days with placebo, p=0.001) 3
• Reduces episode duration (4 days vs 6 days, p<0.001) 3
• Decreases viral shedding time (25 hours vs 58.5 hours, p=0.04) 3
• Increases the proportion of aborted episodes 3

Shorter Course Options

Ultra-short courses are effective alternatives:

• 2-day acyclovir: 800 mg three times daily for 2 days significantly reduces lesion duration, episode length, and viral shedding compared to placebo 3
• Single-day famciclovir: 1 g twice daily (total 2 doses) is as effective as 3-day valacyclovir without shortening time to next recurrence or inducing drug resistance 4

These abbreviated regimens maintain efficacy while improving convenience and potentially reducing cost.

Renal Dose Adjustments

While the provided guidelines don't specify renal dosing, all three antivirals require dose reduction in renal impairment due to renal elimination. Standard adjustments based on creatinine clearance:

Valacyclovir:

• CrCl 30-49 mL/min: 500 mg once daily
• CrCl 10-29 mL/min: 500 mg every 48 hours
• CrCl <10 mL/min: 500 mg every 48 hours or after dialysis

Acyclovir:

• CrCl 10-25 mL/min: 800 mg every 8 hours
• CrCl <10 mL/min: 800 mg every 12 hours

Famciclovir:

• CrCl 40-59 mL/min: 125 mg twice daily
• CrCl 20-39 mL/min: 125 mg once daily
• CrCl <20 mL/min: 125 mg every 48 hours

When to Consider Suppressive Therapy Instead

Switch from episodic to daily suppressive therapy if patients experience ≥6 recurrences per year 1. Suppressive therapy reduces recurrence frequency by ≥75% and may reduce transmission risk, though it doesn't eliminate asymptomatic viral shedding 1.

Severe Disease Requiring Hospitalization

For severe complications (disseminated infection, pneumonitis, hepatitis, meningitis, or encephalitis), use IV acyclovir 5-10 mg/kg every 8 hours for 5-7 days until clinical resolution 1.

Common Pitfalls to Avoid

• Delayed treatment initiation: Efficacy drops dramatically if treatment starts >24 hours after lesion onset
• Inadequate patient education: Patients must understand to self-initiate therapy immediately at first symptoms
• Forgetting renal adjustment: All three drugs accumulate in renal impairment and can cause toxicity
• Confusing HSV-2 meningitis with encephalitis: Meningitis can often be managed with oral therapy after initial IV treatment, while encephalitis requires 14-21 days of IV acyclovir 5
• Using topical acyclovir: This is substantially less effective than oral therapy and should be avoided 6

Drug Resistance Considerations

Acyclovir resistance remains rare in immunocompetent patients even with long-term suppressive therapy 1, 6. Single-day famciclovir does not accelerate resistance development 4. However, immunocompromised patients may develop resistance and require alternative agents like foscarnet or cidofovir 7.